Eketinib hydrochloride can be treated with second-generation targeted drugs, third-generation targeted drugs or anti-angiogenic drugs after drug resistance, and it needs to be judged according to the condition to adopt what treatment method. Ectinib belongs to the first generation of targeted drugs, which is commonly used in non-small cell lung cancer with EGFR gene mutation. When the patient is resistant to this drug, the second and third generation of targeted drugs against EGFR mutation can be used under the guidance of doctor, such as afatinib, ositinib, etc., which can achieve a better therapeutic effect. In addition, anti-tumor neovascularization drugs, such as bevacizumab, can be used to inhibit tumor cell proliferation and metastasis. It is recommended that patients choose the appropriate treatment according to their own condition under the guidance of doctors, and drugs should be used under the guidance of doctors, do not blindly use drugs, so as not to delay the condition.